CDK2 (Cyclin-dependent kinase 2)

These results suggest that PPI exerts antitumor effects against BxPC-3 cells by inhibiting STAT3 phosphorylation.

Furthermore, PMLE treatment significantly activated p53 in A549 cells, followed by increased nuclear translocation, which may account for the up regulation of p16INK4a, p21Cip1, and p27Kip1 proteins. Taken together, our results indicate that PMLE exerts anti-cancer activity in human lung adenocarcinoma by arresting the cell cycle through activation of the p53-dependent pathway.

Accordingly, co-targeting CDK7, which regulates CDK2, CDK4/6, and ERα, additively impacted cell fitness. Collectively, these data reveal a complex, multitiered response to CDK4/6 inhibition, with implications for therapeutic efficacy.

Furthermore, overexpression of Gal-3 and GPC-6 reverses the pro-apoptotic effect of ESPPW, as indicated by restored cycle regulatory proteins (CDK2) expression. In conclusion, these data demonstrate that ESPPW suppresses PDAC cell growth by promoting apoptosis and disrupting the functional activity of Gal-3 and GPC-6.

Collectively, these factorial results provide compelling evidence that propranolol may interact with core oncogenic kinase cluster and potential modulation of the critical signaling cascades implicated in HCC pathogenesis. Collectively, these computational findings support the hypothesis that propranolol possesses the molecular characteristics of a viable therapeutic candidate for HCC, thereby substantiating the need for rigorous experimental and translational investigation to validate its clinical potential.

The potency of compound 4p (IC50 = 148 nM) against CDK2 was much higher than that of roscovitine (IC50 = 700 nM)...ADMET projections further highlighted positive drug-like qualities. Taking together, compound 4p is a promising anticancer candidate that targets CDK2 and exhibits strong in vivo efficacy, with supporting molecular evidence.

In parallel, the transfection of tumour cells with pure synthetic miR160b-5p-a microRNA identified in M. sylvestris flowers and predicted to target the human CDK2 transcript-resulted in gene silencing, thereby suggesting its central role in mediating the cross-kingdom effects of MFE on the investigated cancer models. Overall, these findings open new perspectives on the common mallow as a source of potential antimetastatic compounds and on the possible use of its plant microRNAs in the development of gene therapies.

This study effectively developed a 3-gene prognostic signature comprising MAPK13, INHBA, and LAMB2 using consensus clustering and multifactorial logistic regression. In addition, the functional roles and intrinsic mechanisms of piRPGs in bladder carcinogenesis were comprehensively explored using single-cell sequencing, methylation sequencing, and functional enrichment analysis.

Chalepensin demonstrates promising antitumor activity against L5178Y-R murine lymphoma, along with a favorable acute toxicity profile. These findings support its potential for further preclinical development and warrant additional studies to elucidate its molecular mechanisms and long-term safety.

DEHP may promote the development of BLCA by interacting with key proteins and signaling pathways. This study provides a theoretical basis for understanding the molecular mechanisms of DEHP-induced BLCA and offers references for future prevention and treatment strategies.

Among the series, compounds 6b, 6d, and 6g demonstrated exceptional growth-inhibitory (GI) potency, achieving GI% values of 80.32%, 79.24%, and 86.40%, respectively-substantially outperforming doxorubicin (61.49%)...Several other analogues, including 6d, 6e, 6i, and 6j, also displayed potent cytotoxicity (IC50 < 10 µM), highlighting the broader therapeutic relevance of this scaffold. Collectively, these data position 6g as a compelling multi-target anticancer lead that integrates apoptosis induction, cell-cycle regulation, and angiogenesis suppression-supporting its potential for development as a next-generation broad-spectrum anticancer agent.

In the Ehrlich ascites carcinoma (EAC) model, oral administration of EEJB (400 mg/kg) significantly reduced tumor volume, packed cell volume, and viable cell count, extended mean survival time, and ameliorated tumor-induced hematological and hepatic alterations. These findings position J. betonica L. as a promising plant-derived, multi-target anticancer candidate, meriting further isolation of active principles and mechanistic exploration.